Interagency Coordinating Committee on the Validation of Alternative Methods; Notice of Public Meeting; Request for Public Input, 38906-38907 [2024-10061]

Download as PDF 38906 Federal Register / Vol. 89, No. 90 / Wednesday, May 8, 2024 / Notices Dated: May 2, 2024. B. Kaye Hayes, Deputy Assistant Secretary for Infectious Disease, Department of Health and Human Services. [FR Doc. 2024–10006 Filed 5–7–24; 8:45 am] BILLING CODE 4150–44–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Interagency Coordinating Committee on the Validation of Alternative Methods; Notice of Public Meeting; Request for Public Input AGENCY: National Institutes of Health, HHS. ACTION: Notice. The Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) will hold a public forum to share information and facilitate direct communication of ideas and suggestions from stakeholders. Interested persons may attend in person or view the meeting remotely by webcast. Time will be set aside for questions and public statements on the topics discussed. Registration is requested for attending in person and required for viewing the webcast. Registration is also required for presenting oral statements, whether in person or online. Information about the meeting and registration are available at https://ntp.niehs.nih.gov/go/ iccvamforum-2024. DATES: Meeting: May 20, 2024, 1 p.m. to approximately 5 p.m. EDT; Tuesday, May 21, 2024, 9 a.m. to approximately 4:30 p.m. EDT. Registration for Onsite Meeting: Deadline is May 17, 2024. Registration for Webcast: Deadline is May 21, 2024. Registration for Oral Statements: Deadline is May 15, 2024. Registration to attend in person is requested; registration to view the webcast and to present oral public statements (in person or online) is required. ADDRESSES: Meeting Location: William H. Natcher Conference Center, National Institutes of Health (NIH), Bethesda, MD 20892. Meeting web page: Registration and other meeting materials are at https:// ntp.niehs.nih.gov/go/iccvamforum2024. A preliminary agenda will be posted on this page by May 3. FOR FURTHER INFORMATION CONTACT: Dr. Nicole Kleinstreuer, Director, National lotter on DSK11XQN23PROD with NOTICES1 SUMMARY: VerDate Sep<11>2014 17:03 May 07, 2024 Jkt 262001 Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM), email: nicole.kleinstreuer@nih.gov, telephone: 984–287–3150. SUPPLEMENTARY INFORMATION: Background: ICCVAM, a congressionally mandated committee, coordinates the development and validation of alternative testing strategies that protect human health and the environment while replacing, reducing, or refining animal use. ICCVAM’s goals include promotion of national and international partnerships between governmental and nongovernmental groups, including academia, industry, advocacy groups, and other key stakeholders. To foster these partnerships ICCVAM initiated annual public forums in 2014 to share information and facilitate direct communication of ideas and suggestions from stakeholders (79 FR 25136). This year’s meeting will be held on May 20 and 21, 2024. NICEATM and ICCVAM members will give presentations on current activities related to the development and validation of alternative test methods and approaches. There will be opportunities for participants to ask clarifying or followup questions of the ICCVAM members about their presentations. Instructions for submitting these questions will be provided to webcast viewers prior to the event. The agenda will also include time for public oral statements relevant to the ICCVAM mission and current activities from participants who have registered to do so in advance. Preliminary Agenda and Other Meeting Information: A preliminary agenda will be posted by May 3 at https://ntp.niehs.nih.gov/go/ iccvamforum-2024. Interested individuals are encouraged to visit this web page to stay abreast of the most current meeting information. Meeting and Registration: This meeting is open to the public. The public may attend the meeting at NIH, where attendance is limited only by the space available, or view remotely by webcast. Those planning to attend the meeting in person are encouraged to register at https://ntp.niehs.nih.gov/go/ iccvamforum-2024 by May 15, 2024, to facilitate planning for appropriate meeting space. Registration for the webcast is required and is open through 4:30 p.m. EDT on May 21, 2024, at https://ntp.niehs.nih.gov/go/ iccvamforum-2024. Registrants will receive instructions on how to access and participate in the webcast in the email confirming their registration. PO 00000 Frm 00046 Fmt 4703 Sfmt 4703 NIH visitor and security information is available at https://www.nih.gov/ about/visitor/index.htm. Individuals with disabilities who need accommodation to participate in this event should contact Nicole Kleinstreuer at phone: 919–407–1609 or email: nicole.kleinstreuer@nih.gov. TTY users should contact the Federal TTY Relay Service at 800–877–8339. Requests should be made at least five business days in advance of the event. Request for Oral Public Statements: In addition to time for clarifying or followup questions following scheduled presentations, time will be allotted during the meeting for oral public statements with associated slides on topics relevant to ICCVAM’s mission. Separate registration for those wishing to provide public statements is required and is open through May 15, 2024, at https://ntp.niehs.nih.gov/go/ iccvamforum-2024. Any meeting attendee or webcast viewer may ask clarifying questions during the appropriate times in the agenda. The additional registration is only required for those who wish to give separate public statements. The number and length of presentations may be limited based on available time. Submitters will be identified by their name and affiliation and/or sponsoring organization, if applicable. Participants registered to present oral public statements must email their statement to ICCVAMquestions@niehs.nih.gov by May 15, 2024, to allow time for review by NICEATM and ICCVAM and posting to the meeting page prior to the forum. Persons submitting public statements and/or associated slides should include their name, affiliation (if any), mailing address, telephone, email, and sponsoring organization (if any) with the document. Guidelines for public statements are at https:// ntp.niehs.nih.gov/ntp/about_ntp/ guidelines_public_comments_508.pdf. Persons presenting oral public statements will be contacted to arrange the logistics of their presentations. Presenters should plan for their presentation to run seven minutes or less; each public statement presentation will be followed by up to three minutes to allow for clarifying or follow-up questions. Time allotted for presentations and follow-up questions may be reduced depending on the time available. Written statements on topics relevant to ICCVAM’s mission may be submitted to support an oral public statement or as standalone documents. These should be emailed to ICCVAMquestions@ niehs.nih.gov by May 15, 2024. Public statements received prior to the May 15 E:\FR\FM\08MYN1.SGM 08MYN1 lotter on DSK11XQN23PROD with NOTICES1 Federal Register / Vol. 89, No. 90 / Wednesday, May 8, 2024 / Notices deadline will be distributed to NICEATM and ICCVAM members before the meeting. Written public statements received after the deadline may be reviewed by NICEATM and ICCVAM at a future date. Materials submitted to accompany oral public statements or standalone written statements should include the submitters name, affiliation (if any), mailing address, telephone, email, and sponsoring organization (if any) with the document. Guidelines for public statements are at https://ntp.niehs. nih.gov/ntp/about_ntp/guidelines_ public_comments_508.pdf. Responses to this notice are voluntary. No proprietary, classified, confidential, or sensitive information should be included in statements submitted in response to this notice or presented during the meeting. This request for input is for planning purposes only and is not a solicitation for applications or an obligation on the part of the U.S. Government to provide support for any ideas identified in response to the request. Please note that the U.S. Government will not pay for the preparation of any information submitted or for its use of that information. Background Information on ICCVAM and NICEATM: ICCVAM is an interagency committee composed of representatives from 17 Federal regulatory and research agencies that require, use, generate, or disseminate toxicological and safety testing information. ICCVAM conducts technical evaluations of new, revised, and alternative safety testing methods and integrated testing strategies with regulatory applicability. ICCVAM also promotes the scientific validation and regulatory acceptance of testing methods that more accurately assess the safety and hazards of chemicals and products and replace, reduce, or refine animal use. The ICCVAM Authorization Act of 2000 (42 U.S.C. 285l–3) establishes ICCVAM as a permanent interagency committee of the National Institute of Environmental Health Sciences and provides the authority for ICCVAM involvement in activities relevant to the development of alternative test methods. Additional information about ICCVAM can be found at https:// ntp.niehs.nih.gov/go/iccvam. NICEATM administers ICCVAM, provides scientific and operational support for ICCVAM-related activities, and conducts and publishes analyses and evaluations of data from new, revised, and alternative testing approaches. NICEATM and ICCVAM work collaboratively to evaluate new VerDate Sep<11>2014 17:03 May 07, 2024 Jkt 262001 and improved testing approaches applicable to the needs of U.S. Federal agencies. NICEATM and ICCVAM welcome the public nomination of new, revised, and alternative test methods and strategies for validation studies and technical evaluations. Additional information about NICEATM can be found at https://ntp.niehs.nih.gov/go/ niceatm. Dated: May 3, 2024 Richard P. Woychik, Director, National Institute of Environmental Health Sciences and National Toxicology Program, National Institutes of Health. [FR Doc. 2024–10061 Filed 5–7–24; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Aging; Notice of Closed Meeting Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Aging Special Emphasis Panel; Resilience to AD. Date: June 5, 2024. Time: 11:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Maurizio Grimaldi, M.D., Ph.D., Scientific Review Officer, National Institutes of Health, National Institute on Aging, Gateway Building, 7201 Wisconsin, ROOM 2C218, Bethesda, MD 20892, 301– 496–9374, grimaldim2@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS) 38907 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; NIDDK X01 Central Repository Non-Renewable Sample Access Review Meeting. Date: July 11, 2024. Time: 2:30 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications and/or proposals. Place: National Institutes of Health, NIDDK, Democracy II, Suite 7000A, 6707 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Paul A. Rushing, Ph.D., Scientific Review Officer, Review Branch, Division of Extramural Activities, NIDDK, National Institutes of Health, Room 7345, 6707 Democracy Boulevard, Bethesda, MD 20892–5452, (301) 594–8895, rushingp@ extra.niddk.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS) Dated: May 2, 2024. Miguelina Perez, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2024–10016 Filed 5–7–24; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Dated: May 2, 2024. Miguelina Perez, Program Analyst, Office of Federal Advisory Committee Policy. National Institutes of Health [FR Doc. 2024–10019 Filed 5–7–24; 8:45 am] Pursuant to section 1009 of the Federal Advisory Committee Act, as BILLING CODE 4140–01–P PO 00000 Frm 00047 Fmt 4703 Sfmt 4703 Center for Scientific Review; Notice of Closed Meetings E:\FR\FM\08MYN1.SGM 08MYN1

Agencies

[Federal Register Volume 89, Number 90 (Wednesday, May 8, 2024)]
[Notices]
[Pages 38906-38907]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-10061]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Interagency Coordinating Committee on the Validation of 
Alternative Methods; Notice of Public Meeting; Request for Public Input

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Interagency Coordinating Committee on the Validation of 
Alternative Methods (ICCVAM) will hold a public forum to share 
information and facilitate direct communication of ideas and 
suggestions from stakeholders. Interested persons may attend in person 
or view the meeting remotely by webcast. Time will be set aside for 
questions and public statements on the topics discussed. Registration 
is requested for attending in person and required for viewing the 
webcast. Registration is also required for presenting oral statements, 
whether in person or online. Information about the meeting and 
registration are available at https://ntp.niehs.nih.gov/go/iccvamforum-2024.

DATES: 
    Meeting: May 20, 2024, 1 p.m. to approximately 5 p.m. EDT; Tuesday, 
May 21, 2024, 9 a.m. to approximately 4:30 p.m. EDT.
    Registration for Onsite Meeting: Deadline is May 17, 2024.
    Registration for Webcast: Deadline is May 21, 2024.
    Registration for Oral Statements: Deadline is May 15, 2024.
    Registration to attend in person is requested; registration to view 
the webcast and to present oral public statements (in person or online) 
is required.

ADDRESSES: 
    Meeting Location: William H. Natcher Conference Center, National 
Institutes of Health (NIH), Bethesda, MD 20892.
    Meeting web page: Registration and other meeting materials are at 
https://ntp.niehs.nih.gov/go/iccvamforum-2024. A preliminary agenda 
will be posted on this page by May 3.

FOR FURTHER INFORMATION CONTACT: Dr. Nicole Kleinstreuer, Director, 
National Toxicology Program Interagency Center for the Evaluation of 
Alternative Toxicological Methods (NICEATM), email: 
[email protected], telephone: 984-287-3150.

SUPPLEMENTARY INFORMATION: 
    Background: ICCVAM, a congressionally mandated committee, 
coordinates the development and validation of alternative testing 
strategies that protect human health and the environment while 
replacing, reducing, or refining animal use.
    ICCVAM's goals include promotion of national and international 
partnerships between governmental and nongovernmental groups, including 
academia, industry, advocacy groups, and other key stakeholders. To 
foster these partnerships ICCVAM initiated annual public forums in 2014 
to share information and facilitate direct communication of ideas and 
suggestions from stakeholders (79 FR 25136).
    This year's meeting will be held on May 20 and 21, 2024. NICEATM 
and ICCVAM members will give presentations on current activities 
related to the development and validation of alternative test methods 
and approaches.
    There will be opportunities for participants to ask clarifying or 
follow-up questions of the ICCVAM members about their presentations. 
Instructions for submitting these questions will be provided to webcast 
viewers prior to the event. The agenda will also include time for 
public oral statements relevant to the ICCVAM mission and current 
activities from participants who have registered to do so in advance.
    Preliminary Agenda and Other Meeting Information: A preliminary 
agenda will be posted by May 3 at https://ntp.niehs.nih.gov/go/iccvamforum-2024. Interested individuals are encouraged to visit this 
web page to stay abreast of the most current meeting information.
    Meeting and Registration: This meeting is open to the public. The 
public may attend the meeting at NIH, where attendance is limited only 
by the space available, or view remotely by webcast. Those planning to 
attend the meeting in person are encouraged to register at https://ntp.niehs.nih.gov/go/iccvamforum-2024 by May 15, 2024, to facilitate 
planning for appropriate meeting space. Registration for the webcast is 
required and is open through 4:30 p.m. EDT on May 21, 2024, at https://ntp.niehs.nih.gov/go/iccvamforum-2024. Registrants will receive 
instructions on how to access and participate in the webcast in the 
email confirming their registration.
    NIH visitor and security information is available at https://www.nih.gov/about/visitor/index.htm. Individuals with disabilities who 
need accommodation to participate in this event should contact Nicole 
Kleinstreuer at phone: 919-407-1609 or email: 
[email protected]. TTY users should contact the Federal TTY 
Relay Service at 800-877-8339. Requests should be made at least five 
business days in advance of the event.
    Request for Oral Public Statements: In addition to time for 
clarifying or follow-up questions following scheduled presentations, 
time will be allotted during the meeting for oral public statements 
with associated slides on topics relevant to ICCVAM's mission. Separate 
registration for those wishing to provide public statements is required 
and is open through May 15, 2024, at https://ntp.niehs.nih.gov/go/iccvamforum-2024. Any meeting attendee or webcast viewer may ask 
clarifying questions during the appropriate times in the agenda. The 
additional registration is only required for those who wish to give 
separate public statements. The number and length of presentations may 
be limited based on available time. Submitters will be identified by 
their name and affiliation and/or sponsoring organization, if 
applicable. Participants registered to present oral public statements 
must email their statement to [email protected] by May 15, 
2024, to allow time for review by NICEATM and ICCVAM and posting to the 
meeting page prior to the forum. Persons submitting public statements 
and/or associated slides should include their name, affiliation (if 
any), mailing address, telephone, email, and sponsoring organization 
(if any) with the document. Guidelines for public statements are at 
https://ntp.niehs.nih.gov/ntp/about_ntp/guidelines_public_comments_508.pdf. Persons presenting oral public 
statements will be contacted to arrange the logistics of their 
presentations. Presenters should plan for their presentation to run 
seven minutes or less; each public statement presentation will be 
followed by up to three minutes to allow for clarifying or follow-up 
questions. Time allotted for presentations and follow-up questions may 
be reduced depending on the time available.
    Written statements on topics relevant to ICCVAM's mission may be 
submitted to support an oral public statement or as standalone 
documents. These should be emailed to [email protected] by 
May 15, 2024. Public statements received prior to the May 15

[[Page 38907]]

deadline will be distributed to NICEATM and ICCVAM members before the 
meeting. Written public statements received after the deadline may be 
reviewed by NICEATM and ICCVAM at a future date. Materials submitted to 
accompany oral public statements or standalone written statements 
should include the submitters name, affiliation (if any), mailing 
address, telephone, email, and sponsoring organization (if any) with 
the document. Guidelines for public statements are at https://ntp.niehs.nih.gov/ntp/about_ntp/guidelines_public_comments_508.pdf.
    Responses to this notice are voluntary. No proprietary, classified, 
confidential, or sensitive information should be included in statements 
submitted in response to this notice or presented during the meeting. 
This request for input is for planning purposes only and is not a 
solicitation for applications or an obligation on the part of the U.S. 
Government to provide support for any ideas identified in response to 
the request. Please note that the U.S. Government will not pay for the 
preparation of any information submitted or for its use of that 
information.
    Background Information on ICCVAM and NICEATM: ICCVAM is an 
interagency committee composed of representatives from 17 Federal 
regulatory and research agencies that require, use, generate, or 
disseminate toxicological and safety testing information. ICCVAM 
conducts technical evaluations of new, revised, and alternative safety 
testing methods and integrated testing strategies with regulatory 
applicability. ICCVAM also promotes the scientific validation and 
regulatory acceptance of testing methods that more accurately assess 
the safety and hazards of chemicals and products and replace, reduce, 
or refine animal use.
    The ICCVAM Authorization Act of 2000 (42 U.S.C. 285l-3) establishes 
ICCVAM as a permanent interagency committee of the National Institute 
of Environmental Health Sciences and provides the authority for ICCVAM 
involvement in activities relevant to the development of alternative 
test methods. Additional information about ICCVAM can be found at 
https://ntp.niehs.nih.gov/go/iccvam.
    NICEATM administers ICCVAM, provides scientific and operational 
support for ICCVAM-related activities, and conducts and publishes 
analyses and evaluations of data from new, revised, and alternative 
testing approaches. NICEATM and ICCVAM work collaboratively to evaluate 
new and improved testing approaches applicable to the needs of U.S. 
Federal agencies. NICEATM and ICCVAM welcome the public nomination of 
new, revised, and alternative test methods and strategies for 
validation studies and technical evaluations. Additional information 
about NICEATM can be found at https://ntp.niehs.nih.gov/go/niceatm.

    Dated: May 3, 2024
Richard P. Woychik,
Director, National Institute of Environmental Health Sciences and 
National Toxicology Program, National Institutes of Health.
[FR Doc. 2024-10061 Filed 5-7-24; 8:45 am]
BILLING CODE 4140-01-P


This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.